Cargando…

Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension

METHODS: In this retrospective observational study, we analyzed all patients with pulmonary arterial hypertension undergoing LenusPro® pump implantation between November 2013 and October 2019 at our center. Periprocedural safety was assessed by describing all complications that occurred within 28 da...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamp, Jan C., Fuge, Jan, Karsten, Jan F., Rümke, Stefan, Hoeper, Marius M., Park, Da-Hee, Kühn, Christian, Olsson, Karen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126130/
https://www.ncbi.nlm.nih.gov/pubmed/33992098
http://dx.doi.org/10.1186/s12890-021-01541-3
_version_ 1783693709001359360
author Kamp, Jan C.
Fuge, Jan
Karsten, Jan F.
Rümke, Stefan
Hoeper, Marius M.
Park, Da-Hee
Kühn, Christian
Olsson, Karen M.
author_facet Kamp, Jan C.
Fuge, Jan
Karsten, Jan F.
Rümke, Stefan
Hoeper, Marius M.
Park, Da-Hee
Kühn, Christian
Olsson, Karen M.
author_sort Kamp, Jan C.
collection PubMed
description METHODS: In this retrospective observational study, we analyzed all patients with pulmonary arterial hypertension undergoing LenusPro® pump implantation between November 2013 and October 2019 at our center. Periprocedural safety was assessed by describing all complications that occurred within 28 days after surgery; complications that occurred later were described to assess long-term safety. Clinical outcomes were measured by comparison of clinical parameters and echocardiographic measurements of right ventricular function from baseline to 6-months-follow-up. RESULTS: Fifty-four patients underwent LenusPro® pump implantation for intravenous treprostinil treatment during the investigation period. Periprocedural complications occurred in 5 patients; the only anesthesia-related complication (right heart failure with recovery after prolonged intensive care and death in the further course) occurred in the only patient who underwent general anesthesia. All other patients underwent local anesthesia with or without short-acting (analgo-) sedation. Eighteen long-term complications occurred in 15 patients, most notably pump pocket or catheter related problems. Transplant-free survival rates at 1, 2, and 3 years were 77 %, 56 %, and 48 %, respectively. CONCLUSIONS: Subcutaneous pump implantation under local anesthesia and conscious analgosedation while avoiding intubation and mechanical ventilation is feasible in patients with advanced PAH. Controlled studies are needed to determine the safest anesthetic approach for this procedure. BACKGROUND/OBJECTIVES: Intravenous treprostinil treatment via a fully implantable pump is a treatment option for patients with advanced pulmonary arterial hypertension. However, there is no consensus on the preferred anesthetic approach for the implantation procedure. Primary objective was to assess periprocedural safety with particular attention to feasibility of local anesthesia and conscious analgosedation instead of general anesthesia. Long-term safety and clinical outcomes were secondary endpoints.
format Online
Article
Text
id pubmed-8126130
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81261302021-05-17 Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension Kamp, Jan C. Fuge, Jan Karsten, Jan F. Rümke, Stefan Hoeper, Marius M. Park, Da-Hee Kühn, Christian Olsson, Karen M. BMC Pulm Med Research METHODS: In this retrospective observational study, we analyzed all patients with pulmonary arterial hypertension undergoing LenusPro® pump implantation between November 2013 and October 2019 at our center. Periprocedural safety was assessed by describing all complications that occurred within 28 days after surgery; complications that occurred later were described to assess long-term safety. Clinical outcomes were measured by comparison of clinical parameters and echocardiographic measurements of right ventricular function from baseline to 6-months-follow-up. RESULTS: Fifty-four patients underwent LenusPro® pump implantation for intravenous treprostinil treatment during the investigation period. Periprocedural complications occurred in 5 patients; the only anesthesia-related complication (right heart failure with recovery after prolonged intensive care and death in the further course) occurred in the only patient who underwent general anesthesia. All other patients underwent local anesthesia with or without short-acting (analgo-) sedation. Eighteen long-term complications occurred in 15 patients, most notably pump pocket or catheter related problems. Transplant-free survival rates at 1, 2, and 3 years were 77 %, 56 %, and 48 %, respectively. CONCLUSIONS: Subcutaneous pump implantation under local anesthesia and conscious analgosedation while avoiding intubation and mechanical ventilation is feasible in patients with advanced PAH. Controlled studies are needed to determine the safest anesthetic approach for this procedure. BACKGROUND/OBJECTIVES: Intravenous treprostinil treatment via a fully implantable pump is a treatment option for patients with advanced pulmonary arterial hypertension. However, there is no consensus on the preferred anesthetic approach for the implantation procedure. Primary objective was to assess periprocedural safety with particular attention to feasibility of local anesthesia and conscious analgosedation instead of general anesthesia. Long-term safety and clinical outcomes were secondary endpoints. BioMed Central 2021-05-15 /pmc/articles/PMC8126130/ /pubmed/33992098 http://dx.doi.org/10.1186/s12890-021-01541-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kamp, Jan C.
Fuge, Jan
Karsten, Jan F.
Rümke, Stefan
Hoeper, Marius M.
Park, Da-Hee
Kühn, Christian
Olsson, Karen M.
Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension
title Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension
title_full Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension
title_fullStr Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension
title_full_unstemmed Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension
title_short Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension
title_sort periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126130/
https://www.ncbi.nlm.nih.gov/pubmed/33992098
http://dx.doi.org/10.1186/s12890-021-01541-3
work_keys_str_mv AT kampjanc periproceduralsafetyandoutcomeafterpumpimplantationforintravenoustreprostiniladministrationinpatientswithpulmonaryarterialhypertension
AT fugejan periproceduralsafetyandoutcomeafterpumpimplantationforintravenoustreprostiniladministrationinpatientswithpulmonaryarterialhypertension
AT karstenjanf periproceduralsafetyandoutcomeafterpumpimplantationforintravenoustreprostiniladministrationinpatientswithpulmonaryarterialhypertension
AT rumkestefan periproceduralsafetyandoutcomeafterpumpimplantationforintravenoustreprostiniladministrationinpatientswithpulmonaryarterialhypertension
AT hoepermariusm periproceduralsafetyandoutcomeafterpumpimplantationforintravenoustreprostiniladministrationinpatientswithpulmonaryarterialhypertension
AT parkdahee periproceduralsafetyandoutcomeafterpumpimplantationforintravenoustreprostiniladministrationinpatientswithpulmonaryarterialhypertension
AT kuhnchristian periproceduralsafetyandoutcomeafterpumpimplantationforintravenoustreprostiniladministrationinpatientswithpulmonaryarterialhypertension
AT olssonkarenm periproceduralsafetyandoutcomeafterpumpimplantationforintravenoustreprostiniladministrationinpatientswithpulmonaryarterialhypertension